Advanced Enzymes Q2 EBITDA rises 20% as margin reaches 34%
Key highlights
- Advanced Enzymes’ Q2 FY27 revenue rose 16% year on year to Rs 214.5 crore.
- Q2 FY27 EBITDA increased 20% to Rs 72.1 crore, with an EBITDA margin of 34%.
- Industrial bio-processing was the fastest-growing disclosed segment, with revenue up 43% to Rs 36.5 crore.
- Q2 FY27 PAT before minority interest rose 14% year on year to Rs 51.2 crore.
powered by IRIS

Advanced Enzyme Technologies Limited reported consolidated revenue of Rs 214.5 crore in Q2 FY27, up 16% year on year, while earnings before interest, tax, depreciation and amortisation (EBITDA) rose 20% to Rs 72.1 crore. Advanced Enzymes reported a 34% EBITDA margin, with sequential EBITDA growth of 36% exceeding the 12% increase in revenue.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
How did Advanced Enzymes perform in Q2 FY27?
Advanced Enzymes increased consolidated revenue to Rs 214.5 crore in Q2 FY27 from Rs 184.5 crore in Q2 FY26, a 16% year-on-year rise. EBITDA increased by Rs 12 crore to Rs 72.1 crore from Rs 60.1 crore, producing the company-reported EBITDA margin of 34% for the quarter.
Profit after tax (PAT), before minority interest, rose 14% year on year to Rs 51.2 crore from Rs 44.7 crore. The reported PAT margin was 24% in Q2 FY27. The presentation states that adjustments are made for commission, discount and provision for sales return, without giving a financial value for those items.
Why did Advanced Enzymes' sequential EBITDA grow faster than revenue?
The presentation does not identify a specific cost or operating mechanism behind Advanced Enzymes' faster sequential EBITDA growth. EBITDA rose 36% quarter on quarter to Rs 72.1 crore in Q2 FY27 from Rs 52.9 crore in Q1 FY27, while revenue increased 12% to Rs 214.5 crore from Rs 191.7 crore.
The difference between the reported sequential EBITDA and revenue growth rates was 24 percentage points, and Advanced Enzymes reported a 34% EBITDA margin in Q2 FY27. PAT also rose faster than revenue, increasing 33% to Rs 51.2 crore from Rs 38.6 crore in Q1 FY27, while revenue increased by Rs 22.8 crore.
How does Q2 compare with Advanced Enzymes' first-half results?
Advanced Enzymes' Q2 year-on-year growth rates exceeded its H1 FY27 rates, with revenue up 16% in the quarter compared with 10% in the half year and EBITDA up 20% compared with 7%. H1 FY27 revenue was Rs 406.2 crore against Rs 370.4 crore in H1 FY26, while EBITDA was Rs 125 crore against Rs 116.5 crore.
First-half PAT rose 5% to Rs 89.7 crore from Rs 85.2 crore, compared with the 14% year-on-year increase reported for Q2 alone. Advanced Enzymes reported H1 FY27 EBITDA margin of 31% and PAT margin of 22%, compared with 34% and 24%, respectively, in Q2 FY27.
Got a follow-up? Ask IRIS
Which Advanced Enzymes segments grew fastest in Q2 FY27?
Advanced Enzymes' industrial bio-processing segment recorded the fastest disclosed Q2 growth, with revenue rising 43% year on year to Rs 36.5 crore from Rs 25.5 crore. The segment represented 17% of revenue from operations in Q2 FY27, compared with 12% for animal nutrition and around 60% for human nutrition.
Within industrial bio-processing, food revenue grew 48% year on year to Rs 30.5 crore and represented 14% of Q2 sales. Non-food revenue was Rs 6 crore, up 21% year on year, and represented 3% of sales. The segment increased 19% sequentially, with food up 16% and non-food up 37%.
Animal nutrition revenue increased 37% year on year to Rs 26.5 crore from Rs 19.3 crore, contributing around 12% of Q2 sales. Human nutrition remained the largest disclosed segment at around 60% of sales, but its revenue grew 6% to Rs 128.5 crore from Rs 121.2 crore. Industrial bio-processing and animal nutrition therefore grew faster than human nutrition during the quarter.
What did Advanced Enzymes report for human nutrition?
Advanced Enzymes reported Q2 FY27 human nutrition revenue of Rs 128.5 crore, up 6% year on year and 11% sequentially. The business contributed around 60% of quarterly revenue from operations, making it the largest disclosed segment despite growing more slowly than industrial bio-processing.
For H1 FY27, human nutrition revenue was Rs 244.3 crore, compared with Rs 243.4 crore in H1 FY26, or 0.4% growth. This first-half result differed from the quarter's 6% year-on-year increase, and the presentation does not provide product-level drivers for the change.
Animal nutrition generated Rs 51.7 crore in H1 FY27, up 14% from Rs 45.2 crore, while industrial bio-processing generated Rs 67.1 crore, up 37% from Rs 49.1 crore. Within industrial bio-processing, first-half food revenue was Rs 56.8 crore, up 49%, whereas non-food revenue was Rs 10.3 crore, down 7%.
Conclusion
Advanced Enzymes' Q2 FY27 results improved faster than its first-half aggregate, as quarterly revenue growth of 16%, EBITDA growth of 20% and PAT growth of 14% exceeded the respective H1 FY27 rates of 10%, 7% and 5%. Industrial bio-processing grew 43% and animal nutrition 37% in Q2, while the larger human nutrition segment increased 6%.
The presentation does not disclose a revenue or earnings target, capital plan, operating milestone or date for a future result. The next reported periods will show whether the Q2 pattern persists, particularly the 34% EBITDA margin, the 43% growth in industrial bio-processing and the contrast between human nutrition's 6% quarterly growth and 0.4% H1 FY27 growth.


